Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering speci... Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.8424 | -9.23684210526 | 9.12 | 9.3889 | 8.21 | 3186418 | 8.96285854 | CS |
| 4 | -2.4824 | -23.0706319703 | 10.76 | 12 | 8.21 | 3199981 | 9.52376387 | CS |
| 12 | -3.6424 | -30.5570469799 | 11.92 | 13.34 | 8.21 | 3194883 | 10.2946481 | CS |
| 26 | -12.8424 | -60.8068181818 | 21.12 | 21.4699 | 8.21 | 2820249 | 12.82056189 | CS |
| 52 | -18.9124 | -69.5564545789 | 27.19 | 28.23 | 8.21 | 2123671 | 16.57147735 | CS |
| 156 | -63.1524 | -88.4115917682 | 71.43 | 78.58 | 8.21 | 1502459 | 29.74975771 | CS |
| 260 | -4.6224 | -35.8325581395 | 12.9 | 202.73 | 8.21 | 1393380 | 47.66482563 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
